SITE012-0053

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-04-28

AEs

Serious

Dropout signal

–

Adverse events

severe serious assessed

Grade 3 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-05-14 (study day 2); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 9); relationship: N

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-21 (study day 9); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-05-23 (study day 11); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-06-04 (study day 23); relationship: not assessed

Data queries

No data queries.